Regencell Bioscience Holdings (RGC) Debt Ratio (2020)
Regencell Bioscience Holdings (RGC) reported Debt Ratio of 5.97 for Q2 2020.
Regencell Bioscience Holdings (RGC) Debt Ratio (2020) Analysis & Trends
Regencell Bioscience Holdings has reported Debt Ratio for 1 years, with the latest figure at 5.97 in Q2 2020.
- For the quarter ending Q2 2020, Debt Ratio changed N/A year-over-year to 5.97; the trailing twelve-month figure through Jun 2020 stood at 5.97 (changed N/A YoY), and the FY2020 full-year result was 5.97, changed N/A from the prior year.
- Debt Ratio for Q2 2020 stood at 5.97.
- The five-year high for Debt Ratio was 5.97 in Q2 2020, with the low at 5.97 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.42 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 0.60 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.01 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.30 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 0.35 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 0.24 |
| 10 | Regencell Bioscience Holdings | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 5.97 |